Shares of Marksans Pharma Ltd were trading flat on 8th August after touching a day’s high of Rs 217.49, despite the company securing final approval from the United States Food and Drug Administration (USFDA) for Omeprazole delayed-release tablets used to treat heartburn.

The USFDA has granted final approval to Marksans Pharma Inc., a wholly-owned subsidiary of Marksans Pharma Ltd. This approval is for its Abbreviated New Drug Application (ANDA) of Omeprazole Delayed-Release Tablets 20mg (OTC).

The approved product is the generic version of AstraZeneca’s Prilosec Delayed-Release Tablets 20mg. It is used to treat heartburn and other conditions caused by excess stomach acid. These include gastric and duodenal ulcers, erosive esophagitis, and gastroesophageal reflux disease (GERD).

Currently, the firm’s market capitalisation stands at around Rs 9,658 crore.

At 1:38 PM, the shares of Marksans Pharma were trading 0.63% lower at Rs 213 on NSE.

Got Marksans Pharma Questions? The Analyst is Ready.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!